The designation pertains to the proposed indication of Eye90 microspheres to treat unresectable hepatocellular carcinoma. Credit: Explode / Shutterstock.com.

ABK Biomedical has received breakthrough device designation (BDD) from the US Food and Drug Administration (FDA) for its Eye90 microspheres Y90 radioembolisation device.

This designation pertains to the proposed indication of the device for treating individuals diagnosed with unresectable hepatocellular carcinoma (HCC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Eye90 is claimed to be the only in-procedure imageable Y90 microspheres device.

It incorporates Y90’s radiation therapy with a new imageable glass composition for procedure visualisation through fluoroscopy, X-ray, and CT imaging modalities.

ABK Biomedical president and CEO Mike Mangano said: “This confirms our belief that Eye90 represents an important evolution of radioembolisation technology with the potential to significantly improve patient outcomes.

“Our discussions with the FDA have been productive, and this designation will allow us to streamline interactions with the FDA and bring this product to market in an efficient manner.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In October, the company announced the treatment of the first subject in Route90, a pivotal FDA investigational device exemption (IDE)-approved trial.

It is designed to assess the efficacy and safety of Eye90 microspheres in patients with unresectable HCC.

The response rates of HCC tumours and the duration of response to Eye90 microspheres treatment are the trial’s co-primary endpoints.

Furthermore, the company’s Easi-Vue embolic microspheres offer an imageable embolisation device that facilitates direct visualisation of the microspheres implant during the embolisation procedure.

This device received 510(k) clearance from the FDA for the embolisation of arteriovenous malformations and hypervascular tumours.

ABK Biomedical is focused on the development and commercialisation of medical device therapies for the treatment of patients with benign and malignant hypervascular tumours.